All sponsors

Nanjing IASO Biotechnology Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING0
READOUTS ≤12 MONTHS2
Open Nanjing IASO Biotechnology Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
NCT05091541
P1/2Not yet recruitingB-cell Non-Hodgkin's Lymphoma1252024-10-20
Eque-cel CAR-T Therapy
NCT07055724
P2Not yet recruitingAL Amyloidosis172027-06
FUMANBA-03
NCT06464991
P3Active, not recruitingMultiple Myeloma2602027-08
FUMANBA-04
NCT07510100
P1/2Not yet recruitingRelapsed/Refractory Multiple Myeloma172029-08-31
Equecabtagene Autoleucel Injection (Eque-cel)
NCT07752264
P1/2Not yet recruitingRefractory Immune-mediated Necrotizing Myopathy272030-08-15